✉news TechnologyTechnology first seen 9 h ago, last 9 h ago, peak #27
FDA approves Teva's monthly olanzapine injection for schizophrenia
Original: FDA approves Teva’s monthly injection of olanzapine for schizophrenia
The US Food and Drug Administration has approved Teva's long-acting injectable formulation of olanzapine for treating schizophrenia, the company announced. The monthly injection, known as olanzapine extended-release injectable suspension, offers patients a once-monthly maintenance option instead of daily oral medication. Teva, headquartered in Israel, has been expanding its pipeline of branded and generic neurological treatments, and the approval adds to its central nervous system portfolio.
Why now: Regulatory approval of a new schizophrenia treatment option is significant news for patients, clinicians and investors.
FDATeva Pharmaceutical Industriesolanzapineschizophrenia
Evidence
- FDA approves Teva’s monthly injection of olanzapine for schizophrenia · Pharmaceutical Technology
API: https://socialmediatrends-api.osmike.com/v1/trends/1983362